- Home
- DCOM vs XERS Comparison
DCOM vs XERS Comparison
Compare DCOM & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCOM
- XERS
- Stock Information
- Founded
- DCOM 1864
- XERS 2005
- Country
- DCOM United States
- XERS United States
- Employees
- DCOM N/A
- XERS N/A
- Industry
- DCOM Major Banks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- DCOM Finance
- XERS Health Care
- Exchange
- DCOM Nasdaq
- XERS Nasdaq
- Market Cap
- DCOM 1.2B
- XERS 1.3B
- IPO Year
- DCOM 1996
- XERS 2018
- Fundamental
- Price
- DCOM $27.78
- XERS $9.25
- Analyst Decision
- DCOM Buy
- XERS Strong Buy
- Analyst Count
- DCOM 2
- XERS 7
- Target Price
- DCOM $36.75
- XERS $8.00
- AVG Volume (30 Days)
- DCOM 177.7K
- XERS 2.2M
- Earning Date
- DCOM 10-23-2025
- XERS 11-07-2025
- Dividend Yield
- DCOM 3.59%
- XERS N/A
- EPS Growth
- DCOM N/A
- XERS N/A
- EPS
- DCOM 0.87
- XERS N/A
- Revenue
- DCOM $314,165,000.00
- XERS $246,025,000.00
- Revenue This Year
- DCOM $49.66
- XERS $43.89
- Revenue Next Year
- DCOM $16.29
- XERS $20.40
- P/E Ratio
- DCOM $31.81
- XERS N/A
- Revenue Growth
- DCOM N/A
- XERS 35.62
- 52 Week Low
- DCOM $23.25
- XERS $2.82
- 52 Week High
- DCOM $37.60
- XERS $9.41
- Technical
- Relative Strength Index (RSI)
- DCOM 35.20
- XERS 69.43
- Support Level
- DCOM $27.58
- XERS $7.78
- Resistance Level
- DCOM $30.56
- XERS $8.46
- Average True Range (ATR)
- DCOM 0.98
- XERS 0.41
- MACD
- DCOM -0.28
- XERS 0.09
- Stochastic Oscillator
- DCOM 7.12
- XERS 90.32
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).